Anzeige
Mehr »
Login
Dienstag, 29.11.2022 Börsentäglich über 12.000 News von 681 internationalen Medien
Breaking News! Rallye und Ausbruch die logische Konsequenz?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLU2 ISIN: SE0009414576 Ticker-Symbol: OND 
Tradegate
29.11.22
09:54 Uhr
1,527 Euro
-0,050
-3,14 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOPEPTIDES AB Chart 1 Jahr
5-Tage-Chart
ONCOPEPTIDES AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,5091,53822:56
1,5141,52822:00

Aktuelle News zur ONCOPEPTIDES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrOncopeptides AB: Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank427STOCKHOLM, Nov. 25, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological...
► Artikel lesen
11.11.Oncopeptides AB: Oncopeptides' Pepaxti has been granted marketing authorization in the UK419STOCKHOLM, Nov. 11, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological...
► Artikel lesen
09.11.Oncopeptides AB: Oncopeptides publishes Q3 report 2022262STOCKHOLM, Nov. 9, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological...
► Artikel lesen
09.11.Oncopeptides AB: Oncopeptides announces the market potential for Pepaxti in Europe110STOCKHOLM, Nov. 9, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological...
► Artikel lesen
31.10.Oncopeptides AB: Number of shares and votes in Oncopeptides253STOCKHOLM, Oct. 31, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological...
► Artikel lesen
26.10.Oncopeptides AB: Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen391STOCKHOLM, Oct. 26, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological...
► Artikel lesen
ONCOPEPTIDES Aktie jetzt für 0€ handeln
20.10.Oncopeptides AB: Issue and re-purchase of class C shares for shareholder program and incentive program335STOCKHOLM, Oct. 20, 2022 /PRNewswire/ -- The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) ("Oncopeptides"), a biotech company focused on research and development...
► Artikel lesen
03.10.Oncopeptides AB: Oncopeptides starts commercialization of Pepaxti in Europe - Germany first market324STOCKHOLM, Oct. 3, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological...
► Artikel lesen
23.09.Despite being approved in Europe, Oncopeptides' Pepaxto will remain sidelined in the US7
23.09.Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)366STOCKHOLM, Sept. 23, 2022 /PRNewswire/ -- An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held on Friday, 23 September 2022. At the Extraordinary General Meeting, the...
► Artikel lesen
23.09.Oncopeptides cancer drug Pepaxto gets FDA panel rejection on lack of survival benefit6
23.09.ODAC gives a big thumbs-down to Oncopeptides' dangling accelerated approval in multiple myeloma3
23.09.Oncopeptides AB: Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC334STOCKHOLM, Sept. 23, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...
► Artikel lesen
21.09.Spectrum, Oncopeptides' oncology drugs have much to overcome heading into FDA adcomm11
20.09.FDA slams Spectrum and Oncopeptides cancer drugs over efficacy concerns ahead of ODAC meeting27
20.09.Oncopeptides AB: Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published742STOCKHOLM, Sept. 20, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...
► Artikel lesen
07.09.Oncopeptides AB: Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma355STOCKHOLM, Sept. 7, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...
► Artikel lesen
30.08.Extraordinary General Meeting in Oncopeptides AB (publ)4
19.08.Oncopeptides receives EU marketing authorisation for RRMM therapy8
18.08.Oncopeptides AB: European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma371STOCKHOLM, Aug. 18, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological...
► Artikel lesen
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,7